Vertex Second Phase II Study Supports Telaprevir 24-Week Regimen

Adverse events associated with the hep C treatment are “troublesome,” not “troubling,” Vertex CEO Boger says.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet